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changed between the two time periods. Also, the use of PBSC
instead of BMSC increased (P0.0001). In order to evaluate the
relative importance of these factors a multivariate analysis will be
performed. Conclusion: The pronounced improvement in TRM
during recent years seem to be multi factorial however, an im-
proved donor selection strategy is probably the main cause.
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IMPROVEMENT OF MATCHED SIBLING DONOR ENGRAFTMENT WITH
SIROLIMUS ADDED TO A NON-MYELOABLATIVE CONDITIONING REG-
IMEN
Claxton, D.F.; Ehmann, C.; Shaffer, M.; Rybka, W. Penn State College
of Medicine, Hershey, PA.
Non-myeloablative regimens extend the beneﬁt of allogeneic
hematopoietic transplantation to many otherwise ineligible pa-
tients. Anti-tumor effects are however thought not to occur for
most patients until full donor chimerism is achieved. We have
recently added sirolimus to an established conditioning regimen in
an attempt to optimize engraftment and anti-tumor effects while
minimizing morbid GVHD. We compare results of two sequential
studies conditioning patients with hematological malignancies with
cyclophosphamide (days 7 and 6) and ﬂudarabine (days 7
through 3) prior to matched sibling peripheral blood stem cell
transplantation. All received tacrolimus and methotrexate immu-
noprophylaxis. 9 patients were enrolled in the initial study, and 6/9
also received Campath 1H 20 mg IV on day 7 of the regimen.
The second study has treated 10 patients with sirolimus added to
the immunosuppression and adjusted to 5–15 ng/ml beginning on
day7 (no Campath was given on this study). Tacrolimus has been
tapered off in this protocol between days 30–45, but sirolimus has
continued. Graft versus host disease occurred prior to day 100 in
5/9 patients on protocol 1 and 2/10 patients on protocol 2. In all
cases GVHD was controllable and no patient has died of transplant
related causes. In both protocols all patients showed some degree
of donor engraftment by RFLP or XY FISH analysis by day 30.
Mean fractional peripheral blood donor chimerism values through
day 180 are given in the table below. There is no signiﬁcant
interaction between treatment and time (p-value0.8579), hence
the engraftment curves for the two protocols are parallel. Based on
a repeated measures analysis using general F-statistics, there is a
signiﬁcant treatment effect, with patients on the second protocol
showing an average of 18% higher engraftment (p-value0.0281).
While follow-up is shorter for patients on Protocol 2, 8/10 patients
are beyond 180 days from transplant and the other two have both
achieved 0.98 fractional donor engraftment. We conclude that
our second protocol, using sirolimus with early tapering of tacroli-
mus, appears to yield more rapid and complete donor chimerism
(Table).
Donor Fractional Whole Blood Chimerism
Day 15 Day 30 Day 100 Day 180
Protocol 1 0.51 0.75 0.82 0.81
Protocol 2 with Sirolimus 0.72 0.88 0.99 1.00
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IMATINIB ONLY FOR MOLECULAR RELAPSE IS NOT SUFFICIENT TO
ACHIEVE A DURABLE COMPLETE CHIMERIC STATUS AND MOLECULAR
REMISSION AFTER ALLO HCT IN CML
Soydan, E.; Civriz, S.; Beksac, M.; Koc, H.; Gurman, G.; Ilhan, O.;
Arat, M Ankara University Medical School Department of Hematology,
Ankara, Turkey.
Background: Allogeneic hematopoietic cell transplantation (Al-
loHCT); today, is still the only treatment modality that provides
cure for CML. But relapses after AlloHCT are still an ongoing
problem. In most of these patients donor lymphocyte infusions
(DLI) are effective to achieve molecular remission (MR). Post DLI
aplasia and GVHD are the most important reasons of morbidity
and mortality in these patients. Imatinib is a tyrosine kinase inhib-
itor and blocks CML progenitor cell proliferation. The effect of
imatinib on relapse after AlloHCT has been investigated in a few
studies including patients with chronic and accelerated phase
CML. In this study we aimed to analyze the effect of imatinib on
post AlloHCT molecular relapse. Patients and Method: Imatinib
was applied 400 mg/day p.o. at least for six months to 11 patients;
transplanted from their HLA identical siblings with molecular
relapse. Patients were monitored closely with ATM Multiplex
PCR for chimerism and RQ-PCR (LightCycler, Roche Diagnos-
tics) for bcr-abl/G6PDH. Results: Eleven of the patients were
under imatinib treatment for more than 6 months. Seven of the 11
patients responded to imatinib. At the end of the sixth month
except two patients all of them had donor type chimerism. Peri-
orbital edema developed in 4 of the patients, and none of the
patients had Gr 3–4 GIS and hematologic side effect. After cessa-
tion of the drug ﬁve patients had durable MR and complete
chimeric (CC) status. Two patients with second molecular relapse
and mix chimeric status after imatinib, and four patients with
primary imatinib resistance received DLI. After median 12 (6–20)
months follow up, imatinib sensitive 5 patients were in continuing
MR, imatinib sensitive two patients with second relapse were in
MR and CC after DLI. One of the imatinib refractory patients was
lost after DLI induced acute GVHD in MR, The remaining
patients did not achieve MR. One patient is still receiving DLI,
IFN and imatinib. Conclusion: Imatinib treatment for molecular
relapse after AlloHCT has acceptable adverse event proﬁle and
provides over 60% MR rate but this response was not durable as in
DLI; 25% of the patients experience second relapse early after
cessation of the drug. DLI may achieve MR in 50% of the primary
imatinib resistant patients. Concerning the in vitro effect if ima-
tinib on T cell functions there is an urgent need for prospective
studies comparing DLI and imatinib	DLI with close follow up of
chimerism.
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CAN WE CONSIDER FLUDARABINE/ FULL DOSE I.V. BUSULFAN A RE-
DUCED INTENSITY CONDITIONING REGIMEN?
Chunduri, S.; Jessop, E.; Dobogai, L.; Peace, D.; Saunthararajah, Y.;
Chen, Y.-H.; Mahmud, N.; Maynard, V.; Hoffman, R.; Rondelli, D.
University of Illinois at Chicago, Chicago, IL.
In this study we analyzed 22 patients who received an allogeneic
HSCT from matched related (n17) or unrelated (n5) donors,
and were conditioned with FLU/BU (ﬂudarabine 30 mg/m2/d  4
days followed by single dose i.v. busulfan 3.2 mg/kg/d  4 days)
(n12) or with the FLU/MEL (ﬂudarabine 30 mg/m2/d  5 days
and melphalan 70 mg/m2/d  2 days) (n10) RIC regimen. Me-
dian age was 26 yrs (range: 19–51) in the FLU/BU group and 47
yrs (range: 22–57) in the FLU/MEL group (p0.02). High risk
patients were 8/12 in the FLU/BU group (7 AML in relapse, 1
CML-AP) and 3/10 in the FLU/MEL group (2 resistant NHL and
1 HD). GVHD prophylaxis was FK-506/MTX and in 9/12
FLU/BU cases (including 5 MUD) Thymoglobulin was added. All
FLU/MEL and 6/12 FLU/BU patients received PBSC (median nr.
CD34 cells: 5.0 and 5.9 106/kg, respectively), while 6 FLU/BU
received marrow cells (median nr. CD34 cells: 1.58  106/kg).
Median time to ANC 500 was comparable in PBSC FLU/BU
(d14, range: 11–20), and PBSC FLU/MEL (d12, range: 10–15)
patients, while it was longer in bone marrow FLU/BU (d 22, range:
17–37) patients (p 0.01 and p0.001, respectively). Time to Plt
20K was d 12 (range: 10–16) in the PBSC FLU/MEL group and
d 20 (range: 17–37) in the bone marrow FLU/BUS group. Four of
6 PBSC FLU/BU patients did not have severe thrombocytopenia
(
20K) after transplant. Mucositis  grade 2 was never observed.
Median length of stay in the hospital after transplant was 17 days
(range: 13–37) in PBSC FLU/MEL, 23 days (range: 18–42) in
PBSC FLU/BU and 30 d (range: 22–38) in bone marrow FLU/
BU. Median chimerism levels on d30 after transplant were: 100%
in FLU/MEL and 95% (1 rejection) in FLU/BU. Median fol-
low-up for patients currently alive is 254 days (range: 145–628) in
the FLU/BU group and 636 days (range: 429–715) in the FLU/
MEL group. Acute GVHD grade II-IV was seen in 1 FLU/BU
patient after DLI and in 1 FLU/MEL patient. Chronic GVHD is
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